000			03130nam a22003977a 4500
008			220124s20202020 xxu||||| |||| 00| 0 eng d
022			_a2163-0402
024			_a10.1212/CPJ.0000000000000773 [doi]
024			_aNEURCLINPRACT2019044057 [pii]
024			_aPMC7837428 [pmc]
040			_aOvid MEDLINE(R)
099			_a33520413
245			_aSphenopalatine ganglion block in primary headaches: An American Headache Society member survey.
251			_aNeurology Clinical Practice. 10(6):503-509, 2020 Dec.
252			_aNeurol., Clin. pract.. 10(6):503-509, 2020 Dec.
253			_aNeurology. Clinical practice
260			_c2020
260			_fFY2021
260			_p2020 Dec
265			_sppublish
266			_d2021-02-18
501			_aAvailable online through MWHC library: 2012 - present
520			_aBackground: The sphenopalatine ganglion (SPG), in the pterygopalatine fossa, is a known current and historical target for therapeutic intervention in headache disorders because of its role in cranial autonomics and vasodilation. There remains an overall lack of well-established SPG treatment protocols, particularly with the advent of newer commercial devices.
520			_aConclusions: The variety of responses strongly suggests that clinicians would benefit from formalized protocols for SPG blocks. More experienced clinicians may have developed individualized protocols that they feel are more effective. The lack of evidence-based protocols contribute to clinicians not performing SPG blocks more frequently. Copyright (c) 2019 American Academy of Neurology.
520			_aMethods: A 22 multiple-choice question survey was created to evaluate clinical practice patterns with SPG block and sent to members of the American Headache Society (AHS). Questions focused on determining indications, preferred applicators, medications applied, perceived efficacy, tolerability, and reimbursement.
520			_aResults: One hundred seventy-two of 1,346 (12.8%) AHS members participated. Ninety-three respondents (56.3%) had performed SPG blocks on 50 or fewer patients. The SphenoCath (42.4%) and the Tx360 (41.8%) were the most common methods of application. Ease of use was the top reason for provider preference in applicator type. SPG blocks were mostly used as an as-needed one-time procedure. When a scheduled protocol was used, twice weekly for 6 weeks was most common. Chronic migraine was the most commonly treated headache disorder and rated the most likely to respond to SPG block. Experienced clinicians found SPG more helpful as a stand-alone treatment and tended to report that acute relief was not predictive of enduring response.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Health Research Instituteihriye
657			_aJournal Article
700			_aAilani, Jessica
700			_aMete, Mihriye
790			_aAilani J, Burkett JG, Halker Singh RB, Mete M, Robbins MS, Robertson CE, Saikali NP
856			_uhttps://dx.doi.org/10.1212/CPJ.0000000000000773 _zhttps://dx.doi.org/10.1212/CPJ.0000000000000773
942			_cART _dArticle
999			_c6192 _d6192